A prior study demonstrated that inducible activation of the Wnt/β-catenin pathway by lenalidomide treatment mediated lenalidomide resistance in MM [32], which affects downstream targets, such as CCND1 and MYC. This evidence concerns the gene CCND1 and Miyoshi myopathy.